-
A
CWR22Res Nsi and SPRY2 (Pool) KD cells were subjected to SRB1 KO and/or treatment with ITX5061 as indicated. Cell numbers were normalised to T0 (Day 0) for each cell line (n = 3; *P < 0.05 ANOVA Tukey's test for all cell lines compared to Pool VC).
-
B
HDL uptake in indicated cells grown in medium containing 10% FBS (FM) or 10% charcoal‐stripped serum (ADT) treated with 15 μM ITX5061 (n = 3; *P < 0.05; #
P < 0.05 Nsi ADT CTRL compared to Pool ADT CTRL; ANOVA Tukey's test).
-
C
The effects of ITX5061 on CWR22Res prostate orthografts represented as tumour volume (n = 5 mice per group; #
P < 0.05 for Nsi orthografts; *P < 0.05 for Pool orthografts; ANOVA Tukey's test).
-
D, E
LC‐MS‐based detection of androstenedione (testosterone precursor) (#
P < 0.05 for Nsi orthografts compared to Pool ADT vehicle; *P < 0.05 for Pool orthografts; ANOVA Tukey's test) (D) and testosterone (#
P < 0.05 unpaired two‐tailed Student's t‐test Nsi mock compared to Nsi ADT for respective treatments; *P < 0.05 ANOVA Tukey's test compared to Pool ADT vehicle) (E) in CWR22Res prostate orthografts from mice treated as indicated (n = 3 mice per group).
-
F
Prostate tumour weights from NPS mice treated with ITX5061 (n = 6; *P < 0.05 ANOVA Tukey's test).
-
G
Representative images (n = 5) of H&E and immunostained prostate sections from NPS mice treated with ITX5061. Scale bar = 10 μm.
-
H
Incidence of cumulative visceral metastases was analysed from proximal and distal metastatic sites from mice bearing CWR22Res Nsi or Pool SPRY2 KD orthografts, receiving treatments as indicated. Classification of proximal and distal metastases is shown in
Appendix Fig S1A.
Data Information: In (C–F), each data point represents one independent observation. In (A), each data point represents mean ± SD. In (H), data presented as contingency graph. In (B–F), the data are presented as mean ± SD.
